Elliot Marseille1, Aaron M Harris2, Hacsi Horvath3, Andrea Parriott4, Mohsen Malekinejad5, Noele P Nelson2, Michelle Van Handel6, James G Kahn3. 1. Health Strategies International, Oakland CA, USA. 2. U.S. Centers for Disease Control and Prevention; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, USA. 3. Philip R. Lee Institute for Health Policy Studies, Global Health Sciences, and Global Health Economics Consortium, University of California, San Francisco CA, USA. 4. Philip R. Lee Institute for Health Policy Studies and Consortium to Assess Prevention Economics, University of California, San Francisco CA, USA. 5. Philip R. Lee Institute for Health Policy Studies, Global Health Sciences and Consortium to Assess Prevention Economics, University of California, San Francisco CA, USA. 6. U.S. Centers for Disease Control and Prevention; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, USA; and Corresponding author. Email: mvanhandel@cdc.gov.
Abstract
Background Hepatitis B vaccination is recommended for persons with current or past sexually transmitted infections (STI). Our aim is to systematically assess the association of hepatitis B virus (HBV) sero-markers for current or past infection with syphilis, chlamydia, gonorrhoea, or unspecified STIs. METHODS: We conducted a systematic review and meta-analysis. PubMed, Embase, and Web of Science from 1982 to 2018 were searched using medical subject headings (MeSH) terms for HBV, STIs and epidemiology. We included studies conducted in Organisation for Economic Cooperation and Development countries or Latin America that permit the calculation of prevalence ratios (PRs) for HBV and STIs and extracted PRs and counts by HBV and STI status. RESULTS: Of 3144 identified studies, 43 met inclusion requirements, yielding 72 PRs. We stratified outcomes by HBV sero-markers [surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), combined], STI pathogen (syphilis, gonorrhoea/chlamydia, unspecified), and STI history (current, past) resulting in 18 potential outcome groups, for which results were available for 14. For the four outcome groups related to HBsAg, PR point estimates ranged from 1.65 to 6.76. For the five outcome groups related to anti-HBc, PRs ranged from 1.30 to 1.82; and for the five outcome groups related to combined HBV markers, PRs ranged from 1.15 to 1.89). The median HBsAg prevalence among people with a current or past STI was 4.17; not all studies reported HBsAg. Study settings and populations varied. CONCLUSION: This review found evidence of association between HBV infection and current or past STIs.
Background Hepatitis B vaccination is recommended for persons with current or past sexually transmitted infections (STI). Our aim is to systematically assess the association of hepatitis B virus (HBV) sero-markers for current or past infection with syphilis, chlamydia, gonorrhoea, or unspecified STIs. METHODS: We conducted a systematic review and meta-analysis. PubMed, Embase, and Web of Science from 1982 to 2018 were searched using medical subject headings (MeSH) terms for HBV, STIs and epidemiology. We included studies conducted in Organisation for Economic Cooperation and Development countries or Latin America that permit the calculation of prevalence ratios (PRs) for HBV and STIs and extracted PRs and counts by HBV and STI status. RESULTS: Of 3144 identified studies, 43 met inclusion requirements, yielding 72 PRs. We stratified outcomes by HBV sero-markers [surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), combined], STI pathogen (syphilis, gonorrhoea/chlamydia, unspecified), and STI history (current, past) resulting in 18 potential outcome groups, for which results were available for 14. For the four outcome groups related to HBsAg, PR point estimates ranged from 1.65 to 6.76. For the five outcome groups related to anti-HBc, PRs ranged from 1.30 to 1.82; and for the five outcome groups related to combined HBV markers, PRs ranged from 1.15 to 1.89). The median HBsAg prevalence among people with a current or past STI was 4.17; not all studies reported HBsAg. Study settings and populations varied. CONCLUSION: This review found evidence of association between HBV infection and current or past STIs.
Authors: Eric E Mast; Harold S Margolis; Anthony E Fiore; Edward W Brink; Susan T Goldstein; Susan A Wang; Linda A Moyer; Beth P Bell; Miriam J Alter Journal: MMWR Recomm Rep Date: 2005-12-23
Authors: Cindy M Weinbaum; Ian Williams; Eric E Mast; Susan A Wang; Lyn Finelli; Annemarie Wasley; Stephanie M Neitzel; John W Ward Journal: MMWR Recomm Rep Date: 2008-09-19
Authors: Cindy M Weinbaum; Rob Lyerla; Duncan A Mackellar; Linda A Valleroy; Gina M Secura; Stephanie K Behel; Trista Bingham; David D Celentano; Beryl A Koblin; Marlene Lalota; Douglas A Shehan; Hanne Thiede; Lucia V Torian Journal: Am J Public Health Date: 2008-04-01 Impact factor: 9.308
Authors: Henry Roberts; Deanna Kruszon-Moran; Kathleen N Ly; Elizabeth Hughes; Kashif Iqbal; Ruth B Jiles; Scott D Holmberg Journal: Hepatology Date: 2015-10-27 Impact factor: 17.425
Authors: Winston E Abara; Amir Qaseem; Sarah Schillie; Brian J McMahon; Aaron M Harris; George M Abraham; Robert Centor; Douglas M DeLong; Heather E Gantzer; Carrie A Horwitch; Linda L Humphrey; Janet A Jokela; Joseph Ming Wah Li; Robert H Lohr; Ana María López; Robert M McLean Journal: Ann Intern Med Date: 2017-11-21 Impact factor: 25.391
Authors: David W Hutton; Mehlika Toy; Joshua A Salomon; Erin E Conners; Noele P Nelson; Aaron M Harris; Samuel So Journal: Sex Transm Dis Date: 2022-03-21 Impact factor: 3.868